Quarter
Charts

Proto Labs, Inc.

PRLB

CIK 0001443669 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$136M
↑+12.1% +$15Mvs FY2024 (Q4)
Operating Income
$7M
↓-78.9% -$25Mvs FY2024 (Q4)
Net Income
$6M
↓-81.3% -$26Mvs FY2024 (Q4)
Gross Profit
$60M
↑+16.2% +$8Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
55/100
  • Profitability
    0ROIC 2.6% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 3.49 (above 1.5 = solid)
  • Leverage
    100D/E 0.00 (under 0.5 = conservative)
  • Efficiency
    39Asset Turnover 0.71x (1.0+ = capital-efficient)
  • Growth
    57Revenue YoY +12.1% (10% = solid, 25%+ = elite)
  • Margin Trend
    34Op Margin 5.0% · trend -1.0pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project PRLB's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

14%

Trailing 3-yr CAGR was 13.9%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$53.92
Total enterprise IV
$1.31B
Diluted shares
0.02B
Terminal PV
$975M (75% of total)
Year-5 FCF
$115M
YearProjected FCFDiscounted PV
+1$68M$62M
+2$78M$64M
+3$88M$66M
+4$101M$69M
+5$115M$71M
Terminal$1.57B$975M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$15M
investment in PP&E
Stock buybacks (TTM)
$43M
share count reduction
Stock-based comp (TTM)
$16M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$763M
everything owned
Total liabilities
$89M
everything owed
Stockholders' equity
$674M
shareholder claim
Net debt
$-110M
Net cash position ($110M)

Recent performance · 60 quarters

Revenue↑+12.1% +$15M
$136M
Net Income
$6M
Free Cash Flow↓-49.0% -$8M
$8M
Operating Margin
5.0%

Drill down

PRLB Sankey

See Proto Labs, Inc.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

PRLB Charts

60 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

PRLB Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics